Ascentage Pharma Group International (NASDAQ:AAPG) Sets New 12-Month Low Following Analyst Downgrade

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price hit a new 52-week low during trading on Thursday after JPMorgan Chase & Co. lowered their price target on the stock from $46.00 to $33.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Ascentage Pharma Group International traded as low as $14.55 and last traded at $14.6290, with a volume of 9,357 shares traded. The stock had previously closed at $14.94.

A number of other research firms also recently weighed in on AAPG. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Finally, B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $44.75.

Ascentage Pharma Group International Stock Performance

The business has a fifty day moving average of $16.71 and a 200 day moving average of $19.34. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million during the quarter. On average, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.